Regeneron, Sanofi: First Results from Cholesterol Phase III Look Solid
Favorable topline data from Regeneron Pharmaceuticals Inc. and partner Sanofi SA’s first of a dozen Phase III trials with alirocumab for high cholesterol gave cause for encouragement, but investors must wait for full details regarding the results, as well as adverse events (AEs).
These, along with specifics regarding auto-injectors, will be important in comparing Amgen’s Phase III-stage hyperlipidemia compound which, like alirocumab, is a proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitor.
Outside of the US
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST